Please assess the completion status of the following clinical trial:

Trial Title: Meropenem Dosage Strategy Based on PPK Model

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Sixty years and older patients hospitalized at the Peking University Third Hospital with community-acquired or hospital-acquired lower respiratory tract infection.~* Bacilli was idolated from lower respiratory tract specimens within 48 hours prior to study enrollment.~* The pathogen was sensitive to meropenem.~* Received broad-spectrum antibiotic therapy less than 24 hours, or no improvement after antibiotic therapy and pathogen was resistant to the used antibiotics.~Exclusion Criteria:~* Had documented hypersensitivity to carbapenems.~* More than one pathogenic Gram-negative bacillus was isolated lower respiratory tract specimens.~* Positive HIV antibody titre.~* Had known or suspected tuberculosis or other infections caused by Gram-positive cocci, viruses or fungi at baseline.

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: 95 Years
- Healthy Volunteers: f

Study Arms:
- Control group (Type: ACTIVE_COMPARATOR): The participants in control group will accept routine meropenem therapy
- Study group (Type: EXPERIMENTAL): The participants in study group will accept meropenem therapy based on a PPK and PD model.

Based on this trial design, predict the completion outcome and termination type (if applicable).